Търсене на изпитвания

Активни:

Намерени 4,781 изпитвания Стр. 71 от 240

Набира участници

The Benefits of Virtual Reality in the Care of Elderly People With Psychomotor Disadaptation Syndrome

Psychomotor Disadaptation Syndrome

Psychomotor Disadaptation Syndrome (PMDS) is characterised by a deterioration in postural function, gait and psychomotor automatisms in the elderly. It is often associated with falls and can manifest itself as retropulsion, gait abnormalities, neurological disorders and psycho-behavioural problems. For the majority of these patients, a stay in a geriatric medical and rehabilitation centre is necessary, enabling an objective assessment of these disorders and multi-professional care, including physiotherapists, occupational therapists and adapted physical activity teachers, aimed at restoring safe movement and motor independence. However, rehabilitation relies on traditional exercises that are limited, repetitive and sometimes far removed from everyday activities. Technological innovations such as virtual reality (VR) offer opportunities to improve care by creating immersive environments that reproduce real-life situations. VR could thus help to rehabilitate the motor problems associated with MS. The aim of the VIR-AGE project is to study the clinical benefits of VR in the rehabilitation of hospitalised elderly people suffering from PMDS in terms of functional deficits, particularly motor deficits. The study will take place at the Centre gériatrique Champmaillot of the CHU Dijon Bourgogne. A total of 50 patients with SPDM will take part. The total duration of your participation is 5 weeks.

Начало: 16.07.2025 Край: 01.09.2027 Възраст: от 65 г.

France Centre Hospitalier Universitaire Dijon NCT07026890

Набира участници Фаза 3

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Colon Adenocarcinoma Rectal Adenocarcinoma

Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may include mFOLFOX6 with or without bevacizumab. Researchers want to learn if adding calderasib (the study medicine) and cetuximab to mFOLFOX6 can treat locally advanced or mCRC with the KRAS G12C mutation. Calderasib and cetuximab are targeted therapies. The goals of this study are to learn: * About the safety of calderasib with cetuximab and mFOLFOX6 and if people tolerate the treatments * If people who receive calderasib with cetuximab and mFOLFOX6 live longer without mCRC growing or spreading compared to people who receive mFOLFOX6 with or without bevacizumab.

Начало: 16.07.2025 Край: 27.10.2030 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +22 Merck Sharp & Dohme LLC NCT06997497

Набира участници Фаза 1

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma in Relapse Myeloma Multiple Multiple Myeloma Progression Neoplasms by Histologic Type +10

The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.

Начало: 16.07.2025 Край: 01.05.2042 Възраст: от 18 г. Лечение

Australia, United States Kelonia Therapeutics, Inc. NCT07075185

Набира участници Фаза 2

A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria

Phenylketonuria (PKU)

The goal of this Phase 2, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of oral JNT-517 in adolescents (12 to less than 18 years of age) with PKU. Participants will receive either JNT-517 or placebo and will be blinded to their treatment assignment. Participants will have a 4 in 5 (or 80%) chance of receiving JNT-517. The study will last for up to 63 days including a Screening period, Treatment period and Follow-up period for safety. Participants will: * Take 75 mg JNT-517 or a placebo BID (2x per day) for 28 days * Visit the clinic or have a mobile health nurse visit your home for checkups and tests * Collect urine sample at home and bring to clinic on specified days * Keep a food diary 3 days before each study visit

Начало: 16.07.2025 Край: 09.05.2026 Възраст: 12–17 г.

Australia, United States Otsuka Pharmaceutical Development & Commercialization, NCT06637514

Набира участници Фаза 3

A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition

Kidney Disease

Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that build-up in the kidneys causing swelling (inflammation). Over time, this inflammation may lead to kidney damage and cause the kidneys to no longer work properly. The main aim of this study is to check how well mezagitamab changes protein levels in the urine (proteinuria) compared to placebo in adults with primary IgAN. A placebo looks like medicine but doesn't have any active ingredients in it. Other aims are to check how safe mezagitamab is and how well participants with primary IgAN can tolerate it compared to placebo, and to find out if and how well mezagitamab continues to maintain kidney function over the long term compared to placebo. Participants will be placed in 1 of the 2 treatment groups; the main group and the open-label group. In the main group, participants will be placed in 1 of the 2 treatment groups by chance (either mezagitamab or placebo) at a 2:1 ratio. This means that out of 3 participants, 2 will receive mezagitamab and 1 will receive placebo. The participants will receive either mezagitamab or placebo for almost half a year in two 1-year cycles. They will be observed for another half year in each 1-year cycle and will have check-ups about every month during this time. In the open-label group, a small number of participants who have lower levels of protein in their urine or have kidneys that do not filter the blood well, will receive mezagitamab treatment. This will include participants who have previously received mezagitamab in another study, TAK-079-1006. Every participant will receive mezagitamab in the same way as those in the main group receiving mezagitamab. During the study, participants will visit their study clinic several times.

Начало: 15.07.2025 Край: 14.01.2030 Възраст: от 18 г. Лечение

Argentina, Australia, Austria +23 Takeda NCT06963827

Набира участници Фаза 2

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

Atopic Dermatitis (AD)

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.

Начало: 15.07.2025 Край: 31.03.2027 Възраст: 18–75 г.

Canada, United States Bluefin Biomedicine, Inc. NCT07105488

Набира участници Фаза 1/2

CAR-T Immunotherapy Targeting CD19- ALL

B-cell Leukemia

This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 negative ALL that express CD22, CD123, CD38, CD10, CD20 and TSLPR, as many patients developed CD19-negative disease after CD19 CART immunotherapy. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.

Начало: 15.07.2025 Край: 15.12.2029 Възраст: 6–75 г.

China Shenzhen Geno-Immune Medical Institute NCT04016129

Набира участници

Evaluation of Tenting the Schneiderian Membrane of the Maxillary Sinus Using Titanium Mesh.

Maxillary Sinus Floor Augmentation

Twenty posterior maxillary edentulous sites requiring open sinus augmentation for staged dental implant placement will be studied. Group I (study group) the maxillary sinus membrane will be elevated using titanium mesh fixed by bone screws. Group II (control group) will have stainless steel screws/pins placed bucco-palatally to maintain the elevated membrane and stabilize the formed blood clot. Platelet rich fibrin (PRF) will be placed at the site of elevated membrane in both groups.

Начало: 15.07.2025 Край: 01.12.2026 Възраст: 18–60 г.

Egypt Suez Canal University NCT07035236

Набира участници Фаза 1/2

Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

Acute Myeloid Leukemia

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multi-CAR T cell therapy targeting different AML surface antigens in patients with relapsed or refractory acute myeloid leukemia (AML). Another goal of the study is to learn more about the function of the multi-CAR T cells and their persistency in the patients.

Начало: 15.07.2025 Край: 31.12.2028 Възраст: 2–75 г.

China Shenzhen Geno-Immune Medical Institute NCT03222674

Набира участници Фаза 1/2

Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes

Myelodysplastic Syndromes

The goal of this interventional clinical trial is to evaluate the safety and tolerability of leflunomide in combination with decitabine as treatment for patients with relapsed or refractory myelodysplastic syndromes (R/R MDS). The main question this study aims to answer are to evaluate and estimate the maximum tolerated doses and/or biologically active doses of the combination of leflunomide-decitabine in participants. Decitabine will be administered at a dose of 20 mg/m2 by continuous intravenous infusion over one hour repeated daily for 5 days with repeating cycle every 4 weeks. Leflunomide is administered orally at 10 to 20 mg once daily (without a loading dose) for 14 to 21 days, as part of a 28-day treatment cycle in adult subjects with R/R MDS. After 12 cycles (study duration) responding patients can continue progression with the assigned doses.

Начало: 15.07.2025 Край: 01.10.2028 Възраст: от 18 г.

United States West Virginia University NCT06923488

Набира участници

Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3

COPD Emphysema

The objective of this study is to assess the safety and efficacy of Apreo BREATHE system when used to support native airways and release trapped air in the treatment of adult COPD patients with emphysema suffering from dyspnea due to hyperinflation despite optimal medical treatment. The Apreo BREATHE Airway Scaffold is a permanent implant designed to tent open native airways. The study will include up to 250 participants at up to 25 study centers located in the United States and Europe. Study subjects will be followed for 3 years. The main questions it aims to answer are: Is it safe? Does it work?

Начало: 15.07.2025 Край: 31.12.2029 Възраст: 40–84 г.

Austria, Netherlands, United Kingdom +1 Apreo Health, Inc. NCT06891755

Набира участници

A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

Lung Cancer, Hepatocellular Carcinoma

This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of Life (HRQoL), as well as the effectiveness and safety of Atezolizumab SC in participants treated for selected approved indications in routine clinical practice.

Начало: 15.07.2025 Край: 31.12.2028 Възраст: от 18 г.

Austria, Belgium, Bulgaria +5 Hoffmann-La Roche NCT07284121

Набира участници

Bronchoscopic Microwave Ablation of Lung Tissue in Surgical Candidates - UK

Lung Cancer

This study involves the use of a medical device, the Creo Medical MicroBlate Flex instrument, to heat and destroy lung tumour cells using microwave energy (this is also called ablation). In this study, the investigators are investigating whether the ablation instrument can be used effectively to treat lung tumours or tumours that have spread to the lungs. If successful, using this technology may mean future patients may not need to undergo surgical removal of these types of lung tumours. The aim of this study is to evaluate the safety and performance of the MicroBlate Flex instrument in treating individuals with cancerous lung tumours that are due to be removed by surgery. All participants in the study will undergo the microwave ablation procedure, which is a separate and additional procedure to their surgical procedure. The study, funded by Creo Medical, will be conducted at sites in the UK and Italy, and will involve up to 18 participants.

Начало: 14.07.2025 Край: 01.12.2026 Възраст: от 18 г.

Italy, United Kingdom Creo Medical Limited NCT06869122

Набира участници

Project VIBE: Virtual Intervention for Binge Eating in Adolescents

Obesity Binge-Eating Disorder Binge Eating

The aim of this project is to pilot test a novel mobile app intervention for adolescents with dysregulated eating behaviors and elevated weight status. This intervention will incorporate evidence-informed strategies targeting self-regulation into cognitive-behavioral treatment for maladaptive eating. Adolescents will use the app for 16 weeks and provide feedback on its usability and effectiveness in managing dysregulated eating.

Начало: 14.07.2025 Край: 30.05.2027 Възраст: 13–19 г.

United States University of Pittsburgh NCT06819813

Набира участници Фаза 2

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

Lupus Erythematosus, Systemic Lupus Nephritis

The purpose of this study is to evaluate the efficacy, safety and drug levels of CC-97540 in participants with active systemic lupus erythematosus (SLE) including lupus nephritis with inadequate response to glucocorticoids and at least 2 immunosuppressants.

Начало: 14.07.2025 Край: 15.06.2032 Възраст: от 16 г.

Argentina, Austria, Belgium +13 Juno Therapeutics, Inc., a Bristol-Myers Squibb Company NCT07015983

Набира участници

Evaluation of a Diagnostic Software for Coronary Artery Disease Using Retrospective CCTA Data (CODEX-1 Study)

Coronary Artery Disease Atherosclerosis Myocardial Ischemia

The CODEX-1 study is a multicenter retrospective observational study designed to assess the diagnostic performance of a novel software application for coronary artery disease (CAD) evaluation. The application integrates automated stenosis detection, CT-derived fractional flow reserve (CT-FFR), and plaque quantification, all performed on-site. A total of 1,000 patients who previously underwent coronary computed tomography angiography (CCTA) and diagnostic invasive coronary angiography (ICA) and/or other non-invasive imaging will be included. The study compares the diagnostic outputs of the software to current clinical practice and expert adjudication, focusing on CAD-RADS categorization, prediction of the need for percutaneous coronary intervention (PCI), and reduction in unnecessary ICA procedures.

Начало: 14.07.2025 Край: 30.04.2027 Възраст: от 18 г.

France, Netherlands, Spain Instituto de Investigación Biomédica de Salamanca NCT06977295

Набира участници Фаза 3

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

COVID-19 Infection

This is a Phase 3, randomized, actively controlled, double-blinded, double-dummy, superiority study to evaluate the efficacy and safety of ibuzatrelvir alone and in combination with remdesivir IV compared to remdesivir IV alone for the treatment of symptomatic COVID-19 in severely immunocompromised adult participants who are non-hospitalized or are hospitalized for observation or study intervention administration but do not require supplemental oxygen for COVID-19.

Начало: 14.07.2025 Край: 06.05.2027 Възраст: от 18 г.

Argentina, Belgium, Brazil +15 Pfizer NCT07013474

Набира участници Фаза 1/2

Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care

Shock, Cardiogenic

The objective of this Phase 1b trial is to evaluate the safety and tolerability of procizumab, a monoclonal antibody under development for the treatment of cardiogenic shock (CS). CS is a life-threatening hypoperfusion of vital organs that frequently results in death. In addition to safety and tolerability, pharmacokinetics and pharmacodynamics of procizumab are evaluated to define the optimum phase 2 dose (P2D) of procizumab.

Начало: 13.07.2025 Край: 01.12.2026 Възраст: 18–80 г.

Armenia, Belgium, Czechia +3 4TEEN4 Pharmaceuticals GmbH NCT06832722

Набира участници

This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab

Chronic Obstructive Pulmonary Disease

The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma. The study will focus on the early treatment response, treatment outcomes and the change in asthma control of benralizumab therapy in a real-world setting in China. This study will also describe the physician-reported reasons for discontinuation and switching of benralizumab therapy.

Начало: 11.07.2025 Край: 31.12.2027

China AstraZeneca NCT06862206

Набира участници Фаза 2

ERAS Protocols in Breast Conserving Surgery

Breast Cancer Postoperative Recovery

Enhanced Recovery After Surgery (ERAS) protocols have been of increasing interest in the surgical community for decades. The emphasis has been development of protocols to maximize pain control post-operatively without the use of opioids. While this approach has been studied extensively in the oncology surgery literature, little data exists on the utility of ERAS protocols in the setting of breast conserving surgery (BCS), which is a type of surgery to remove breast cancer while saving as much of the breast as possible. The purpose of this study is to determine the utility of implementing ERAS protocols in breast cancer patients undergoing breast conserving surgery. Study participants will be randomized to either ERAS protocol or standard peri-operative care without ERAS. The study will assess the how many opioid prescriptions are given in the first week after surgery and how much pain participants report right after surgery. Investigators will also look at how long participants stay in the recovery room and if medicine for nausea is needed.

Начало: 11.07.2025 Край: 01.02.2029 Възраст: от 19 г.

United States University of Nebraska NCT06938581

1 … 69 70 71 72 73 … 240